Clinical Trial Results:
Multicenter, dose response, randomized, double blin, parallel, 3 arms, placebo controlled clinical trial to evaluate the efficacy and the safety of subcutaneous CDP870 (certolizumab pegol) at 2 different 12 weeks dose regimens followed by a minimum of 12 wks of follow-up without treatment (or until relapse) in subjects suffering from moderate- to-severe chronic plaque psoriasis who are candidates for systemic therapy and/or phototherapy and/or photochemotherapy.
Summary
|
|
EudraCT number |
2005-002141-39 |
Trial protocol |
DE |
Global completion date |
14 Nov 2006
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
25 Dec 2016
|
First version publication date |
25 Dec 2016
|
Other versions |
|
Summary report(s) |
synopsis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.